低临床活动度评分的「进展性」甲状腺眼病:香港某三级中心1439例患者的临床表现
该研究前瞻性队列纳入2014至2023年香港某三级中心1439例甲状腺眼病患者,采用盲法回顾病历和眼眶影像。结果显示38%为中重度、10%为视力威胁型,但其临床活动度评分仅分别为2.4±1.4和2.6±1.5;仅18%患者临床活动(CAS≥3)。作者指出仅依据高CAS的诊疗路径存在局限。
要点
- 1439例甲状腺眼病患者中,547例(38%)为中重度、150例(10%)为视力威胁型,其CAS仅2.4±1.4和2.6±1.5。
- 仅18%患者临床活动(CAS≥3),34%表现为「低CAS、进展性」中重度或视力威胁型甲状腺眼病。
- 男性和40岁后发病与更高的CAS和NOSPEC评分相关(均p<0.05)。
核心结论
- 约三分之一(34%)队列表现为「低CAS、进展性」中重度或视力威胁型甲状腺眼病,仅五分之一(18%)临床活动(CAS≥3)。
- 结果显示了现有「仅高CAS」路径的局限和未满足需求,尤其在管理非炎症性甲状腺眼病方面,该病在非白种人群中常见。
研究设计与样本
- 前瞻性队列,并对病历和眼眶影像进行盲法回顾。
- 连续纳入2014年至2023年间就诊于香港中文大学甲状腺眼病门诊的1439例甲状腺眼病患者。
主要发现
- 1439例患者中70%为女性、98%为汉族、26%为既往或当前吸烟者,就诊年龄43±5.9岁,首次甲状腺眼病症状至门诊评估间隔6±3个月。
- 85%患者有Graves病,12%就诊前接受过放射性碘治疗,35%有自身免疫性甲状腺疾病家族史。
- 基线促甲状腺激素受体抗体、甲状腺刺激性免疫球蛋白和甲状腺过氧化物抗体分别在受检者的75%、69%和57%中升高。
- 6%诊断为甲状腺功能正常型甲状腺眼病,与不对称表现相关(p<0.001)。
- 最常见体征为眼球突出(69%)、上睑退缩(53%)、肿胀(36%)、结膜充血(34%)和下睑退缩(32%)。
关键数值与推荐
- 547例(38%)表现为中重度甲状腺眼病,其临床活动度评分为2.4±1.4;150例(10%)为视力威胁型,评分为2.6±1.5。
- 471例(33%)接受静脉甲泼尼龙,361例(25%)接受眼眶放疗,263例(18%)接受保类固醇免疫抑制剂,138例(9%)接受手术减压。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To report the presenting clinical, serological and treatment profiles of 1439 patients with thyroid eye disease (TED) from a tertiary centre in Hong Kong. STUDY POPULATIONS: Consecutive patients with TED presented to the Thyroid Eye Clinic (TEC), the Chinese University of Hong Kong between 2014 and 2023. METHODS: Prospective cohort and masked review of medical records and orbital images. RESULTS: A total of 1439 (70% female, 98% Han Chinese) patients with TED (26% ex/current smoker), presented at 43±5.9 years old, were reviewed. The first TED symptoms to TEC evaluation was 6±3 months. 85% had Graves' disease and 12% were given radioactive iodine before presentation. 35% of patients had a family history of autoimmune thyroid diseases. Baseline thyroid-stimulating hormone receptor antibody, thyroid-stimulating immunoglobulin and thyroid peroxidase antibody were elevated in 75%, 69% and 57% tested. Euthyroid TED (E-TED) was diagnosed in 6%, associated with asymmetric presentation (p<0.001). The most common signs were exophthalmos (69%), upper eyelid retraction (53%), swelling (36%), conjunctival injection (34%) and lower eyelid retraction (32%). Notably, 547 (38%) presented with moderate-to-severe and 150 (10%) vision-threatening TED, whose clinical activity score (CAS) was just 2.4±1.4 and 2.6±1.5, respectively. Male and TED onset after 40 were associated with higher CAS and NOSPEC (No physical signs or symptoms, Only signs, Soft tissue involvement, Proptosis, Extraocular muscle signs, Corneal involvement, and Sight loss) score (both p<0.05). 471 (33%), 361 (25%), 263 (18%) and 138 (9%) patients received intravenous methylprednisolone, orbital radiotherapy, steroid-sparing immunosuppressants and surgical decompression, respectively. CONCLUSIONS: Around one-third (34%) of our cohort presented with 'low-CAS, progressive', moderate-to-severe or vision-threatening TED, while only one-fifth (18%) were clinically active (CAS≥3). Our results showed the limitations and unmet need of the existing 'high-CAS only' approach, especially in managing 'non-inflammatory' TED, prevalent in non-Caucasian populations.
引用
- Lai KKH, Aljufairi FMAA, Sebastian JU, et al. Low clinical activity score, 'progressive' thyroid eye disease: presentations of 1439 patients from a tertiary centre in Hong Kong. Br J Ophthalmol. 2025. PMID: 39798945. doi:10.1136/bjo-2024-325346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。